Drug Trial Radar · NCT04656288
A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Jan 15, 2021
Primary completion
Mar 15, 2021
Study completion Mar 15, 2021
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Dec 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
BI 764198 is intended to be used in patients hospitalized for COVID-19 at risk of respiratory complications. The present trial will investigate the relative bioavailability of BI 764198 administered as capsules versus tablets in a first part, and the relative bioavailability and food effect of four oral formulations: the newly developed tablet formulation under fed and fasted conditions as well as suspension from capsules and suspension from tablets in a second part.
Conditions
- Healthy
Interventions
BI 764198 - Formula ADrug
BI 764198
BI 764198 - Formula BDrug
BI 764198
BI 764198 - Formula CDrug
BI 764198
BI 764198 - Formula DDrug
BI 764198
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)Time frame: up to 4 days per period
- Part 1: Cmax (maximum measured concentration of the analyte in plasma)Time frame: up to 4 days per period
- Part 2: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)Time frame: up to 5 days per period
- Part 2: Cmax (maximum measured concentration of the analyte in plasma)Time frame: up to 5 days per period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Belgium NV Research Unit Stuivenberg
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.